Gilead Sciences, Inc.
NEWS
The FDA rejected Gilead’s New Drug Application, citing Chemistry Manufacturing and Controls (CMC) problems associated with the compatibility of the drug with the proposed container vial.
The end of February picks up significantly from early this year for the U.S. Food and Drug Administration and its PDUFA dates.
BioSpace compared the 43 healthcare and life science companies on Newsweek’s list of America’s Most Responsible Companies for 2022 with that of our own 2022 Best Places to Work.
Clinical Catch-Up for February 21
HOOKIPA Pharma Inc.’s shares have soared after stating it amended and restated a collaboration and license agreement with Gilead Sciences to develop immunotherapies against HIV.
The EMA’s safety committee has announced that they are reviewing reports of menstrual disorders after people received COVID-19 vaccinations from Pfizer-BioNTech and Moderna.
Here’s a look at five companies that produced non-vaccine treatments for COVID-19.
Antiviral pills against COVID-19 show promise for treating the disease, but they are not broadly accessible yet.
Gilead Sciences revealed in a call with analysts that the hold has now been expanded to additional magrolimab studies.
JOBS
IN THE PRESS